ZA202100919B - Anti-fc epsilon-r1 alpha (fcer1a) antibodies, bispecific antigen-binding molecules that bind fcer1a and cd3, and uses thereof - Google Patents
Anti-fc epsilon-r1 alpha (fcer1a) antibodies, bispecific antigen-binding molecules that bind fcer1a and cd3, and uses thereofInfo
- Publication number
- ZA202100919B ZA202100919B ZA2021/00919A ZA202100919A ZA202100919B ZA 202100919 B ZA202100919 B ZA 202100919B ZA 2021/00919 A ZA2021/00919 A ZA 2021/00919A ZA 202100919 A ZA202100919 A ZA 202100919A ZA 202100919 B ZA202100919 B ZA 202100919B
- Authority
- ZA
- South Africa
- Prior art keywords
- epsilon
- alpha
- fcer1a
- antibodies
- bind
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862721921P | 2018-08-23 | 2018-08-23 | |
| PCT/US2019/047601 WO2020041537A1 (en) | 2018-08-23 | 2019-08-22 | Anti-fc epsilon-r1 alpha (fcer1a) antibodies, bispecific antigen-binding molecules that bind fcer1a and cd3, and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202100919B true ZA202100919B (en) | 2025-10-29 |
Family
ID=67876086
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2021/00919A ZA202100919B (en) | 2018-08-23 | 2021-02-10 | Anti-fc epsilon-r1 alpha (fcer1a) antibodies, bispecific antigen-binding molecules that bind fcer1a and cd3, and uses thereof |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11578127B2 (https=) |
| EP (1) | EP3840841A1 (https=) |
| JP (2) | JP7402223B2 (https=) |
| KR (1) | KR20210049863A (https=) |
| CN (1) | CN112888482B (https=) |
| AU (1) | AU2019325565B2 (https=) |
| BR (1) | BR112021003023A2 (https=) |
| CA (1) | CA3109513A1 (https=) |
| CL (2) | CL2021000437A1 (https=) |
| CO (1) | CO2021003608A2 (https=) |
| EA (1) | EA202190601A1 (https=) |
| IL (1) | IL280745B1 (https=) |
| MX (1) | MX2021002165A (https=) |
| MY (1) | MY204368A (https=) |
| PH (1) | PH12021550322A1 (https=) |
| SG (1) | SG11202101608XA (https=) |
| WO (1) | WO2020041537A1 (https=) |
| ZA (1) | ZA202100919B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3109513A1 (en) | 2018-08-23 | 2020-02-27 | Regeneron Pharmaceuticals, Inc. | Anti-fc epsilon-r1 alpha (fcer1a) antibodies, bispecific antigen-binding molecules that bind fcer1a and cd3, and uses thereof |
| US20230056380A1 (en) * | 2020-01-31 | 2023-02-23 | Randy Leiman Allen | Methods and kit for detection of analytes |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| AU2005282720B2 (en) | 2004-09-02 | 2011-08-04 | Genentech, Inc. | Anti-FC-gamma RIIB receptor antibody and uses therefor |
| JP5307708B2 (ja) | 2006-06-02 | 2013-10-02 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒトｉｌ−６受容体に対する高親和性抗体 |
| MY192182A (en) | 2009-06-26 | 2022-08-04 | Regeneron Pharma | Readily isolated bispecific antibodies with native immunoglobulin format |
| SMT202600080T1 (it) | 2010-02-08 | 2026-03-09 | Regeneron Pharma | Topo con catena leggera comune |
| WO2012142286A1 (en) * | 2011-04-12 | 2012-10-18 | University Of Cincinnati | Methods for suppressing allergic reactions |
| WO2012169741A2 (ko) | 2011-06-07 | 2012-12-13 | (주)네오팜 | ＦｃεＲＩ 특이적 인간 항체 및 이를 포함하는 알레르기 질환 치료 또는 진단용 조성물 |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| EP2837637A1 (en) | 2013-08-16 | 2015-02-18 | SuppreMol GmbH | Novel anti-FcyRIIB IgG-type antibody |
| CN104293738A (zh) | 2013-09-11 | 2015-01-21 | 李莉 | 一种抗人FcεRⅠα亚基单克隆抗体及其应用 |
| EP2982693A1 (en) * | 2014-08-07 | 2016-02-10 | Affimed Therapeutics AG | CD3 binding domain |
| SG11201701028SA (en) | 2014-08-13 | 2017-03-30 | Suppremol Gmbh | Novel antibodies directed to fc gamma receptor iib and fc epsilon receptor |
| CN104800164B (zh) | 2015-04-13 | 2017-11-07 | 上海市第一人民医院 | 一种雷公藤免疫纳米粒及用途 |
| AU2016325630B2 (en) | 2015-09-23 | 2022-11-17 | Regeneron Pharmaceuticals, Inc. | Optimized anti-CD3 bispecific antibodies and uses thereof |
| CA3020633A1 (en) | 2016-04-13 | 2017-10-19 | Sanofi | Trispecific and/or trivalent binding proteins |
| JP7066690B2 (ja) | 2016-09-23 | 2022-05-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗ｍｕｃ１６（ムチン１６）抗体 |
| CA3109513A1 (en) | 2018-08-23 | 2020-02-27 | Regeneron Pharmaceuticals, Inc. | Anti-fc epsilon-r1 alpha (fcer1a) antibodies, bispecific antigen-binding molecules that bind fcer1a and cd3, and uses thereof |
-
2019
- 2019-08-22 CA CA3109513A patent/CA3109513A1/en active Pending
- 2019-08-22 BR BR112021003023-9A patent/BR112021003023A2/pt unknown
- 2019-08-22 KR KR1020217008580A patent/KR20210049863A/ko active Pending
- 2019-08-22 EP EP19765582.2A patent/EP3840841A1/en active Pending
- 2019-08-22 WO PCT/US2019/047601 patent/WO2020041537A1/en not_active Ceased
- 2019-08-22 MY MYPI2021000853A patent/MY204368A/en unknown
- 2019-08-22 JP JP2021510030A patent/JP7402223B2/ja active Active
- 2019-08-22 SG SG11202101608XA patent/SG11202101608XA/en unknown
- 2019-08-22 CN CN201980069380.5A patent/CN112888482B/zh active Active
- 2019-08-22 IL IL280745A patent/IL280745B1/en unknown
- 2019-08-22 EA EA202190601A patent/EA202190601A1/ru unknown
- 2019-08-22 US US16/547,910 patent/US11578127B2/en active Active
- 2019-08-22 AU AU2019325565A patent/AU2019325565B2/en active Active
- 2019-08-22 MX MX2021002165A patent/MX2021002165A/es unknown
-
2021
- 2021-02-10 ZA ZA2021/00919A patent/ZA202100919B/en unknown
- 2021-02-15 PH PH12021550322A patent/PH12021550322A1/en unknown
- 2021-02-19 CL CL2021000437A patent/CL2021000437A1/es unknown
- 2021-03-19 CO CONC2021/0003608A patent/CO2021003608A2/es unknown
-
2023
- 2023-01-12 US US18/153,522 patent/US12441797B2/en active Active
- 2023-02-13 CL CL2023000442A patent/CL2023000442A1/es unknown
- 2023-10-03 JP JP2023172194A patent/JP7541167B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP7402223B2 (ja) | 2023-12-20 |
| AU2019325565A1 (en) | 2021-03-11 |
| CN112888482B (zh) | 2024-06-25 |
| WO2020041537A1 (en) | 2020-02-27 |
| SG11202101608XA (en) | 2021-03-30 |
| US12441797B2 (en) | 2025-10-14 |
| US20230331845A1 (en) | 2023-10-19 |
| US11578127B2 (en) | 2023-02-14 |
| EP3840841A1 (en) | 2021-06-30 |
| KR20210049863A (ko) | 2021-05-06 |
| CL2023000442A1 (es) | 2023-11-24 |
| JP2021533806A (ja) | 2021-12-09 |
| WO2020041537A8 (en) | 2020-09-10 |
| JP7541167B2 (ja) | 2024-08-27 |
| CL2021000437A1 (es) | 2021-09-03 |
| BR112021003023A2 (pt) | 2021-05-11 |
| CA3109513A1 (en) | 2020-02-27 |
| US20200062844A1 (en) | 2020-02-27 |
| MY204368A (en) | 2024-08-26 |
| CN112888482A (zh) | 2021-06-01 |
| JP2023171909A (ja) | 2023-12-05 |
| AU2019325565B2 (en) | 2025-09-04 |
| IL280745B1 (en) | 2026-02-01 |
| IL280745A (en) | 2021-04-29 |
| EA202190601A1 (ru) | 2021-07-14 |
| CO2021003608A2 (es) | 2021-04-30 |
| PH12021550322A1 (en) | 2021-10-04 |
| MX2021002165A (es) | 2021-07-16 |
| NZ772900A (en) | 2025-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2025005515A (es) | Anticuerpos anti-bcma x anti-cd3 biespecificos y usos de estos | |
| MX2021006971A (es) | Anticuerpos anti-muc16 x anti-cd28 biespecificos y usos de estos. | |
| JOP20230312A1 (ar) | أجسام مضادة لـ ccr8 واستخداماتها | |
| MX2020013804A (es) | Anticuerpos anti-psma x anti-cd28 biespecíficos y usos de estos. | |
| SA522431672B1 (ar) | Cd3 أجسام مضادة للارتباط بـ | |
| JOP20210071A1 (ar) | أجسام مضادة مثبّتة trem2 | |
| EA202191580A1 (ru) | Биспецифичные антитела анти-cd28 x анти-cd22 и их применение | |
| MX2024005027A (es) | Anticuerpos de union a cd3. | |
| PH12021550322A1 (en) | Anti-fc epsilon-r1 alpha (fcer1a) antibodies, bispecific antigen-binding molecules that bind fcer1a and cd3, and uses thereof | |
| PH12018550179A1 (en) | Anti-pd-1 antibodies, method for producing same and method for using same | |
| JOP20190248A1 (ar) | بروتينات ربط مولد ضد trem2 واستخداماته | |
| EA201990781A9 (ru) | Анти-steap2 антитела, конъюгаты антитело-лекарственное средство и биспецифические антигенсвязывающие молекулы, которые связывают steap2 и cd3, и их применение | |
| EA201990171A1 (ru) | Биспецифичное антитело против egfr и против cd3 и его применения | |
| MX2020008183A (es) | Anticuerpos especificos para cd70 y sus usos. | |
| WO2020076969A3 (en) | Anti-lap antibody variants and uses thereof | |
| MX2024005841A (es) | Moleculas de union a cd32b x cd79b para usarse como medicamentos para el tratamiento de enfermedades o trastornos inflamatorios y para reducir las respuestas inmunitarias. | |
| MX2022009815A (es) | Moleculas de union biespecificas. | |
| MX2023012300A (es) | Anticuerpos humanos contra artemina y metodos de uso de estos. | |
| EA202190314A1 (ru) | Биспецифические анти-bcma x анти-cd3 антитела и способы их применения | |
| MX2025010217A (es) | Anticuerpos multiespecificos anti-cd3 y metodos de uso | |
| TH2101000210A (th) | ไบสเปซิฟิกแอนติ-BCMA x แอนติ-CD3 แอนติบอดี และการใช้แอนติบอดีดังกล่าว | |
| EA202191677A1 (ru) | Биспецифичные антитела анти-muc16 x анти-cd28 и варианты их применения | |
| PH12022553391A1 (en) | Humanized anti-emap ii therapeutic antibodies | |
| TH1901000154A (th) | แอนติบอดีต้าน pd-1, วิธีการผลิตและวิธีการใช้ของสิ่งดังกล่าว | |
| EA202190089A1 (ru) | Биспецифичные антитела анти-psma x анти-cd28 и их применения |